% | $
Quotes you view appear here for quick access.

Sony Corporation Message Board

  • zany4biotech zany4biotech Jun 16, 1998 1:58 PM Flag


    biotech efforts close in on cancer
    By Kitta
    MacPherson 06/14/98
    Inc., nestled as a corporate tenant in the sprawling
    Exxon Research and Engineering complex in the Hunterdon
    County hillside, was spun out of Essex Chemical
    Corporation in 1989 to explore the potential of an antibody
    technology conceived by two Dartmouth University professors.
    Its hopes are based on a technology known as
    bispecific antibodies.
    Over the course of time, company
    scientists encountered what their colleagues in other
    biotech firms found: The basic idea was sound, it was
    just a matter of refinement. In the lab, though,
    nothing is straightforward.
    Normal antibodies trawl
    the bloodstream, protecting the body against
    invaders. Medarex's antibodies are hybrids with a one-two
    punch. They attach themselves to invader cells with one
    arm, then grab killer cells known as macrophages with
    another. One particular "receptor" on the macrophage,
    discovered by scientists to be an especially lethal trigger
    unleashing unabashed tumor- killing cells, fits especially
    well with the Medarex antibody.
    The company has a
    host of cancer drugs in late-stage clinical trials.

    PRINCETON and ANNANDALE, N.J., June 15 /PRNewswire/ --
    Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc.
    (Nasdaq: MEDX) announced today a research agreement
    involving Medarex's HuMAb-Mouse(TM) technology that creates
    high affinity, fully human antibodies. Bristol-Myers
    Squibb will use the HuMAb-Mouse to create human
    antibodies to multiple antigens for use in its drug
    discovery programs.
    The agreement includes the option
    for Bristol-Myers Squibb to commercialize these
    antibodies with terms that could result in over $20 million
    in license fees and milestone payments, plus
    royalties. This is Medarex's sixth collaboration with
    outside partners involving the HuMAb-Mouse.

    "Bristol-Myers Squibb is an ideal partner for Medarex's
    HuMAb-Mouse technology," said Donald L. Drakeman, President
    and Chief Executive Officer of Medarex. "We are very
    excited to collaborate with an innovative leader in the
    pharmaceutical industry. Bristol-Myers Squibb's interest in
    human antibodies emphasizes the potential of our
    Currently, Medarex has five ongoing
    partnerships for the HuMAb-Mouse technology with Centocor,
    Inc.; Eisai Co., Ltd., Japan; ErythroMed, Inc.;
    LeukoSite, Inc.; and Schering AG, Germany. Potential
    revenues from these collaborations exceed $93 million from
    licensing fees, milestone payments and manufacturing
    revenues, plus royalties on commercial sales.
    is a biopharmaceutical company developing
    antibody-based therapeutics. The Company employs several core
    technologies including Bispecific antibodies, which enhance
    and direct the body's own immune system to fight
    disease; the HuMAb-Mouse(TM) antibody development system
    for the creation of high affinity human antibodies;
    and immunotoxin technology. Medarex has five products
    in clinical development, including MDX-RA for the
    prevention of secondary cataracts, the anti-cancer
    Bispecifics MDX-210 and MDX-447, MDX-33 for autoimmune
    disease, and MDX-22 for acute myeloid leukemia.

    Medarex Presents at BIO '98 Investor & Partnering
    ConferenceANNANDALE, N.J., June 15 /PRNewswire/ -- Medarex, Inc.
    (Nasdaq: MEDX - news) unveiled its plans to build a broad
    antibody franchise in a presentation at the BIO '98
    Investor & Partnering Conference in New York City today. �


20.75-0.45(-2.12%)Feb 9 4:02 PMEST